Tony LI, CFA

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

Precision Scientific is an innovative translational medicine company with CRO services, dedicated to enhancing cancer care. The self-developed cutting-edge AI technology ALBERT (AI-driven Big data analytics for Effective Response of cancer Therapy) is a machine learning-based analysis of multi-omics data using data mining and predictive algorithms. It provides solution for oncology research, including drug target discovery, biomarker identification, indication selection, drug resistance mechanism evaluation, and combo therapy strategy. The company provides integrated CRO services, including top-tier central laboratory full-services, clinical development, biomarker discovery & companion diagnostic development, biometrics, regulatory strategy, and commercialization capabilities. Precision Scientific has established numerous global collaborations with top biotechnology and pharmaceutical companies, academic and healthcare institutions. It also delivery of clinical diagnostic services to national hospitals with the mission of advancing precision medicine.

chassis electronics

TRANSSION HOLDINGS is a company based out of 上海, Shanghai Shi, China.

传音控股致力于成为新兴市场消费者最喜爱的智能终端产品和移动互联服务提供商。自公司成立以来，传音一直着力为用户提供优质的以手机为核心的多品牌智能终端，并基于自主研发的智能终端操作系统和流量入口，为用户提供移动互联网服务。传音旗下拥有新兴市场知名手机品牌TECNO、itel及Infinix，还包括数码配件品牌Oraimo、家用电器品牌Syinix以及售后服务品牌Carlcare。 经过多年的发展，传音现已成为全球新兴市场手机行业的中坚力量。2019年传音手机出货量1.37亿部，根据 IDC统计数据，全球市场占有率8.1%，排名第四；非洲市场占有率52.5%，排名第一；印度市场占有率6.8%，排名第五；孟加拉国市场占有率15.6%，排名第二。 在知名泛非商业杂志《African Business》（2020年6月版）发布的“2019/2020年度最受非洲消费者喜爱的品牌”百强榜中，传音旗下三大手机品牌TECNO、itel及Infinix分别位列第5、21及27名。 2019年，传音荣获“中国民营企业500强”、“中国民营企业制造业500强”、“广东省百强民营企业”、“深圳500强企业”等殊荣。2019年9月30日，传音控股在上海证券交易所科创板成功挂牌上市。 传音分别在中国上海和深圳建立了自主研发中心，通过手机供应链的深度定制合作，实现融合创新。传音拥有研发人员1,500多人，主要集中在手机产品硬件、软件及移动互联网开发等方面。传音通过持续加大研发投入不断强化差异化的产品竞争力，扩大在新兴市场本地化科技创新方面的竞争优势，提升用户价值与体验。 传音在全球设立多个生产制造中心，包括中国、埃塞俄比亚、印度、孟加拉国等。其售后服务品牌Carlcare在全球拥有2,000多个售后服务网点（含第三方合作网点），在海外建立了7大售后维修中心。传音与谷歌、Facebook、微软、联发科、Orange、沃达丰等全球知名企业强强合作，未来将持续稳步地向前发展。 智能移动终端是非洲用户连接互联网的主要方式。传音旗下手机品牌均搭载了深度定制的智能终端操作系统（OS），包括HiOS、itelOS和XOS（以下统称“传音OS”）。目前，传音OS已成为非洲等全球主要新兴市场的主流操作系统之一。围绕传音OS，传音开发了应用商店、游戏中心、广告分发平台以及手机管家等诸多的工具类应用程序。 同时，传音与网易等多家国内领先的互联网公司，在音乐、游戏、短视频、内容聚合及其他应用领域进行出海战略合作，积极开发和孵化移动互联网产品。已合作开发出5款月活跃用户超过1,000万的应用程序。 目前，传音全球销售网络已覆盖70多个国家和地区。

DJI is the global leader in developing and manufacturing innovative drone and camera technology for commercial and recreational use. DJI was founded and is run by people with a passion for remote-controlled helicopters and experts in flight-control technology and camera stabilization. The company is dedicated to making aerial technology accessible, reliable and easy to use for creators, innovators and businesses around the world. DJI has expanded its expertise and innovative technology to enterprises, government agencies and different industries around the world. DJI Enterprise was formed in order to help businesses realize the potential of aerial technology in their operations. DJI has expanded its enterprise solutions to include aerial platforms, payloads and analytic tools that can be deployed today for businesses across the agriculture, construction, infrastructure, energy, public safety sectors, and more. UAV-powered solutions enable operators to streamline workflows, empower staff, digitize operations and make daily processes less time consuming and more cost effective, preparing businesses to meet the needs of tomorrow’s workplace. DJI’s global operations currently span across the Americas, Europe and Asia, and its revolutionary products and solutions have been chosen by customers in over 100 countries for applications in filmmaking, recreation and enterprises across different industries. For more information, visit our websites: www.dji.com and https://enterprise.dji.com/ Contact us: https://enterprise-insights.dji.com/linkedin-contact-us Follow us on Twitter: www.twitter.com/DJIGlobal and www.twitter.com/DJIenterprise Follow us on Facebook: www.facebook.com/DJI Subscribe to our YouTube Channel: www.youtube.com/DJI and www.youtube.com/c/DJIEnterprise

Fong Capital Partners (FCP) is a dual-currency private equity investment firm specializing in the technology and healthcare sectors. With offices in Hong Kong, Beijing and Shanghai, FCPs core team has collaborated for over a decade, accumulating extensive experience managing both USD and RMB funds. The AUM the firm managed has exceeded USD 1 billion. Guided by an investment philosophy that emphasizes navigating economic cycles, deep industry engagement, precise strategic positioning, and responsible investment, FCP has consistently delivered robust and sustained returns to investors over the past ten years, earning recognition from institutional investors internationally.

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

Maison Capital is a well-established private equity firm focusing on the consumer technology, consumer service and consumer lifestyle sectors predominantly in mainland China. Since our establishment in 2004, we have successfully invested in numerous market leaders and grown together with these companies over the decade. We are a disciplined investor that looks for long-term core value in businesses, and have built a strong and stable track record with years of deep industry connection and research. We aspire to build a platform for our team members to further their career ambitions, and to support them through our internal network and training system to grow intellectually and professionally. As an organi-zation, we value integrity, team collaboration and excellence.